Emicizumab for hemophilia A: interim analysis of the real-world EMIIL study

(4:1econd)

Emicizumab for the Treatment of Hemophilia

(9:42)

Appropriate Selection of Emicizumab for Hemophilia

(7:45)

Emicizumab for Hemophilia: HAVEN Trial Data Results

(1:15)

Optimizing Emicizumab Therapy in Hemophilia Treatment

(5:23)

The impact of emicizumab on the hemophilia treatment landscape

(1:27)

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated...

(49:57)

HAVEN 7: emicizumab prophylaxis for the treatment of infants with severe hemophilia A

(6:11)

Real-world adherence and persistence to emicizumab in patients with hemophilia A in the US

(5:28)

Efficacy, Approval, and Personal Experience with Emicizumab

(6:49)

Emicizumab for children with hemophilia A: A journey through the ages

(22:43)

Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A

(2:15)

How emicizumab has changed hemophilia A management

(3:45)

HEMLIBRA® (emicizumab-kxwh) Mechanism of Action for Haemophilia A

(6:56)

Emicizumab - Personal Experiences

(59:56)

Emi \u0026 Me - Exploring the impact of treatment with emicizumab

(3:15)

Primary analysis of HAVEN 7: emicizumab prophylaxis in infants with severe hemophilia A

(8:37)

Emicizumab Prophylaxis in Hemophilia A

(2:6)

The impact of emicizumab prophylaxis on caregivers' burden for patients with hemophilia A

(1:43)

Emicizumab Prophylaxis and Management of Breakthrough Bleeding Events

(52:25)